NDLI: Personalized medicine in gastric cancer: Where are we and where are we going?

Content Provider	PubMed Central
Author	Jácome, Alexandre A. Coutinho, Anelisa K. Lima, Enaldo M. Andrade, Aline C. Santos, José Sebastião Dos
Copyright Year	2016
Abstract	Despite improvements in adjuvant therapies for gastric cancer in recent years, the disease is characterized by high recurrence rates and a dismal prognosis. The major improvement in the treatment of recurrent or metastatic gastric cancer in recent years has been the incorporation of trastuzumab, a monoclonal antibody that inhibits human epidermal growth factor receptor 2 (HER2) heterodimerization, after the demonstrated predictive value of the overexpression and/or amplification of this receptor. Beyond HER2, other genetic abnormalities have been identified, and these mutations may be targetable by tyrosine kinase inhibitors or monoclonal antibodies. The demonstration of four distinct molecular subtypes of gastric cancer by the Cancer Genome Atlas study highlight the enormous heterogeneity of the disease and its complex interplay between genetic and epigenetic alterations and provide a roadmap to implement genome-guided personalized therapy in gastric cancer. In the present review, we aim to discuss, from a clinical point of view, the genomic landscape of gastric cancer described in recent studies, the therapeutic insights derived from these findings, and the clinical trials that have been conducted and those in progress that take into account tailored therapies for gastric cancer.
Related Links	http://dx.doi.org/10.3748/wjg.v22.i3.1160
Starting Page	1160
File Format	PDF
ISSN	10079327
e-ISSN	22192840
Journal	World Journal of Gastroenterology
Issue Number	3
Volume Number	22
Language	English
Publisher	Baishideng Publishing Group Inc
Publisher Date	2016-01-01
Access Restriction	Open
Rights Holder	Baishideng Publishing Group Inc
Subject Keyword	Gastroenterology Research in Higher Education
Content Type	Text
Resource Type	Article
Subject	Gastroenterology

Sl.	Authority	Responsibilities	Communication Details
1	Ministry of Education (GoI), Department of Higher Education	Sanctioning Authority	https://www.education.gov.in/ict-initiatives
2	Indian Institute of Technology Kharagpur	Host Institute of the Project: The host institute of the project is responsible for providing infrastructure support and hosting the project	https://www.iitkgp.ac.in
3	National Digital Library of India Office, Indian Institute of Technology Kharagpur	The administrative and infrastructural headquarters of the project	Dr. B. Sutradhar bsutra@ndl.gov.in
4	Project PI / Joint PI	Principal Investigator and Joint Principal Investigators of the project	Dr. B. Sutradhar bsutra@ndl.gov.in Prof. Saswat Chakrabarti will be added soon
5	Website/Portal (Helpdesk)	Queries regarding NDLI and its services	support@ndl.gov.in
6	Contents and Copyright Issues	Queries related to content curation and copyright issues	content@ndl.gov.in
7	National Digital Library of India Club (NDLI Club)	Queries related to NDLI Club formation, support, user awareness program, seminar/symposium, collaboration, social media, promotion, and outreach	clubsupport@ndl.gov.in
8	Digital Preservation Centre (DPC)	Assistance with digitizing and archiving copyright-free printed books	dpc@ndl.gov.in
9	IDR Setup or Support	Queries related to establishment and support of Institutional Digital Repository (IDR) and IDR workshops	idr@ndl.gov.in

Bloating and functional gastro-intestinal disorders: Where are we and where are we going?

Bio-feedback treatment of fecal incontinence: Where are we, and where are we going?

Multidisciplinary treatment of rectal cancer in 2014: Where are we going?

Multimodal treatment of gastric cancer in the west: Where are we going?

Gastric Cancer Due to Chronic H. pylori Infection: What We Know and Where We Are Going

Prostate cancer: where are we going?

Neoplasia: Where We Have Been and Where We Are Going

Natural orifice transluminal endoscopic surgery: Where are we going?

International Hepato-Pancreato-Biliary Association: who are we and where are we going?

Personalized medicine in gastric cancer: Where are we and where are we going?

Similar Documents

Bloating and functional gastro-intestinal disorders: Where are we and where are we going?

Bio-feedback treatment of fecal incontinence: Where are we, and where are we going?

Multidisciplinary treatment of rectal cancer in 2014: Where are we going?

Multimodal treatment of gastric cancer in the west: Where are we going?

Gastric Cancer Due to Chronic H. pylori Infection: What We Know and Where We Are Going

Prostate cancer: where are we going?

Neoplasia: Where We Have Been and Where We Are Going

Natural orifice transluminal endoscopic surgery: Where are we going?

International Hepato-Pancreato-Biliary Association: who are we and where are we going?

Personalized medicine in gastric cancer: Where are we and where are we going?